147 related articles for article (PubMed ID: 24172207)
1. Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.
Deng J; Letai A
Breast Cancer Res; 2013; 15(5):317. PubMed ID: 24172207
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.
Vaillant F; Merino D; Lee L; Breslin K; Pal B; Ritchie ME; Smyth GK; Christie M; Phillipson LJ; Burns CJ; Mann GB; Visvader JE; Lindeman GJ
Cancer Cell; 2013 Jul; 24(1):120-9. PubMed ID: 23845444
[TBL] [Abstract][Full Text] [Related]
3. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
4. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
5. ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca
Jakubowska MA; Kerkhofs M; Martines C; Efremov DG; Gerasimenko JV; Gerasimenko OV; Petersen OH; Bultynck G; Vervliet T; Ferdek PE
Br J Pharmacol; 2019 Nov; 176(22):4402-4415. PubMed ID: 30266036
[TBL] [Abstract][Full Text] [Related]
6. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
[TBL] [Abstract][Full Text] [Related]
7. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
8. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.
Vogler M; Dinsdale D; Dyer MJ; Cohen GM
Br J Haematol; 2013 Oct; 163(1):139-42. PubMed ID: 23826785
[No Abstract] [Full Text] [Related]
9. Low DEDD expression in breast cancer cells indicates higher sensitivity to the Bcl-2-specific inhibitor ABT-199.
Liu D; Qin X; Sun Z; Hou S; Lv Q
Biochem Biophys Res Commun; 2020 May; 525(3):549-556. PubMed ID: 32113682
[TBL] [Abstract][Full Text] [Related]
10. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Ng SY; Davids MS
Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352
[TBL] [Abstract][Full Text] [Related]
11. BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?
Martin LA; Dowsett M
Cancer Cell; 2013 Jul; 24(1):7-9. PubMed ID: 23845438
[TBL] [Abstract][Full Text] [Related]
12. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Souers AJ; Leverson JD; Boghaert ER; Ackler SL; Catron ND; Chen J; Dayton BD; Ding H; Enschede SH; Fairbrother WJ; Huang DC; Hymowitz SG; Jin S; Khaw SL; Kovar PJ; Lam LT; Lee J; Maecker HL; Marsh KC; Mason KD; Mitten MJ; Nimmer PM; Oleksijew A; Park CH; Park CM; Phillips DC; Roberts AW; Sampath D; Seymour JF; Smith ML; Sullivan GM; Tahir SK; Tse C; Wendt MD; Xiao Y; Xue JC; Zhang H; Humerickhouse RA; Rosenberg SH; Elmore SW
Nat Med; 2013 Feb; 19(2):202-8. PubMed ID: 23291630
[TBL] [Abstract][Full Text] [Related]
13. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
14. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Bogenberger JM; Delman D; Hansen N; Valdez R; Fauble V; Mesa RA; Tibes R
Leuk Lymphoma; 2015 Jan; 56(1):226-9. PubMed ID: 24707940
[No Abstract] [Full Text] [Related]
16. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
[TBL] [Abstract][Full Text] [Related]
17. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
18. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.
Aka Y; Karakas B; Acikbas U; Basaga H; Gul O; Kutuk O
Int J Biochem Cell Biol; 2021 Aug; 137():106028. PubMed ID: 34171479
[TBL] [Abstract][Full Text] [Related]
19. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
20. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Pan R; Hogdal LJ; Benito JM; Bucci D; Han L; Borthakur G; Cortes J; DeAngelo DJ; Debose L; Mu H; Döhner H; Gaidzik VI; Galinsky I; Golfman LS; Haferlach T; Harutyunyan KG; Hu J; Leverson JD; Marcucci G; Müschen M; Newman R; Park E; Ruvolo PP; Ruvolo V; Ryan J; Schindela S; Zweidler-McKay P; Stone RM; Kantarjian H; Andreeff M; Konopleva M; Letai AG
Cancer Discov; 2014 Mar; 4(3):362-75. PubMed ID: 24346116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
